HYL-9
General Information
DRACP ID DRACP01198
Peptide Name HYL-9
Sequence GIMSSLMKALAAHIAK
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin AMP
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
A549 | Lung adenocarcinoma | Carcinoma | IC50=4.75±0.33 µmol/L | MTT assay | 72h | Patent |
Hep-G2 | Hepatoblastoma; Hepatoblastoma | Blastoma | IC50=8.04±0.27 µmol/L | MTT assay | 72h | Patent |
HCT 116 | Colon carcinoma | Carcinoma | IC50=7.22±0.21 µmol/L | MTT assay | 72h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C72H128N20O19S2
Absent amino acids CDEFNPQRTVWY
Common amino acids A
Mass 190981
Pl 10.81
Basic residues 3
Acidic residues 0
Hydrophobic residues 8
Net charge 3
Boman Index 1000
Hydrophobicity 91.25
Aliphatic Index 122.5
Half Life
Mammalian: 30 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Structural modification and antitumor activity of antimicrobial peptide HYL
Doi 10.1016/j.cclet.2019.10.013
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available